Chong Kun Dang Pharmaceutical

Peak

Phase 4 marketed antihypertensive generating sustained revenue from established cardiovascular franchise.

Cantabell

Share Interview Share Compensation

Help build intelligence for Chong Kun Dang Pharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hy

Essential Hypertension

N/A

Clinical Trials (1)

NCT03063697Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure

N/A

Atorvastatin

Coronary Artery Disease

N/A

Clinical Trials (1)

NCT03414840Assessment of Change in Atherosclerotic Plaque by Serial CCTA

N/A

Tacrobell capsule 1mg

Immunosuppression

N/A

Clinical Trials (1)

NCT01910077Bioequivalence Study of Tacrobell Capsule 1mg to Prograf Capsule 1mg

N/A

Comparison of Myocardial Infarction Patients Who Were Prescribed a Novel Antiplatelet Agent or Clopi

Myocardial Infarction

N/A

Clinical Trials (1)

NCT05599152Comparison of Myocardial Infarction Patients Who Were Prescribed a Novel Antiplatelet Agent or Clopidogrel

N/A

Duvie

Type2 Diabetes

N/A

Clinical Trials (1)

NCT05043467Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus

N/A

SGLT2 inhibitor

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT06838286Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

N/A

Retrospective Observational Study on GERD Management in General Hospitals in Korea

Gastroesophageal Reflux Disease (GERD)

N/A

Clinical Trials (1)

NCT06974903Retrospective Observational Study on GERD Management in General Hospitals in Korea

N/A

Umbilical Cord Blood therapy

Cerebral Palsy

N/A

Clinical Trials (1)

NCT01991145Allogeneic UCB Therapy With EPO in Children With CP

N/A

SGLT2 inhibitors

Acute Myocardial Infarction (AMI)

N/A

Clinical Trials (1)

NCT07198191SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

N/A

Dual-combination therapy

Helicobacter Pylori Infection

N/A

Pantoprazole

N/A

Clinical Trials (1)

NCT02159976Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea

N/A

Amlodipine 10mg

Type II Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT02064556CKD-330 Drug-Drug Interaction Study (Amlodipine)

Phase 1

Clopidogrel

Coronary Artery Disease

Phase 1

Clinical Trials (1)

NCT01663038Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination

Phase 1

D569 Tab.

Rheumatoid Arthritis

Phase 1

Clinical Trials (1)

NCT03858725Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers

Phase 1

NESP 60μg

Anemia

Phase 1

Clinical Trials (1)

NCT01684605Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers

Phase 1

CKD-379

Phase 1

Clinical Trials (1)

NCT06652971A Clinical Trial to Evaluate the Food Effect of CKD-379

Phase 1

CKD 501

Phase 1

Clinical Trials (1)

NCT04431687A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)

Phase 1

CKD-330 16/5mg - B

Phase 1

Clinical Trials (1)

NCT02811731Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B

Phase 1

CKD-393 formulation I

Type II Diabetes

Phase 1

Clinical Trials (1)

NCT04768673A Study to Investigate the PK and Safety of CKD-393

Phase 1

CKD-398

Type II Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT04869800Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg

Phase 1

CKD-379 I

Phase 1

Clinical Trials (1)

NCT05452525Pharmacokinetics and Safety/Tolerability Profile of CKD-379

Phase 1

Drug: CKD-391, QD, PO

Dyslipidemias

Phase 1

Clinical Trials (1)

NCT05634447A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391

Phase 1

XELJANZ 5Mg Tablet

Rheumatoid Arthritis

Phase 1

Clinical Trials (1)

NCT03868072Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers

Phase 1

CKD-519

Dyslipidemia

Phase 1

Clinical Trials (1)

NCT02156544Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Phase 1

CKD-702

Non-Small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT04667975The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy

Phase 1

D113

Chronic Heart Failure

Phase 1

Clinical Trials (1)

NCT05089279Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers

Phase 1

CKD-387

Type II Diabetes

Phase 1

Clinical Trials (1)

NCT03646799Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults

Phase 1

CKD-333, formula I

Phase 1

Clinical Trials (1)

NCT03849287Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults

Phase 1

Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG

Diabetes Mellitus, Type II

Phase 1

Clinical Trials (1)

NCT06483243Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.

Phase 1

Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg

Phase 1

Clinical Trials (1)

NCT02685774A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers

Phase 1

CKD-330 16/5mg - A

Phase 1

Clinical Trials (1)

NCT02801526Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A

Phase 1

CKD-383

Phase 1

Clinical Trials (1)

NCT05897216Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029

Phase 1

CKD-320, D012

T2DM (Type 2 Diabetes Mellitus)

Phase 1

Clinical Trials (1)

NCT04035538A Clinical Study to Compare the Safety and Pharmacokinetics of CKD-320 and D012

Phase 1

Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg

Essential Hypertension

Phase 1

Clinical Trials (1)

NCT01842256Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.

Phase 1

CKD-501, D759, D150

Phase 1

Clinical Trials (1)

NCT04706286Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

Phase 1

CKD-383

Phase 1

Clinical Trials (1)

NCT05816759Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

Phase 1

SKYRIZI

Psoriasis

Phase 1

Clinical Trials (1)

NCT07258745Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants

Phase 1

CKD-381

GERD

Phase 1

Clinical Trials (1)

NCT03444402A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects

Phase 1

CKD-348

Phase 1

Clinical Trials (1)

NCT06112678A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)

Phase 1

CKD-519 50mg 2Tabs.

Dyslipidemia

Phase 1

Clinical Trials (1)

NCT02623868Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.

Phase 1

CKD-501

Central Nervous System Diseases

Phase 1

Clinical Trials (1)

NCT04334213A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150

Phase 1

Memantine Tab. 10mg

Phase 1

Clinical Trials (1)

NCT03569579CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)

Phase 1

CKD-501

Type II Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01341392Drug-drug Interaction Study(CKD-501, Amlodipine)

Phase 1

NESP 60μg

Anemia

Phase 1

Clinical Trials (1)

NCT01685671Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers

Phase 1

Luckyvec 400mg film coated tablet

Chronic Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT01270984Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects

Phase 1

D308 10mg Tab.

Phase 1

Clinical Trials (1)

NCT03601910Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg

Phase 1

CKD-386

Hypertension and Dyslipidemia

Phase 1

Clinical Trials (1)

NCT04694989A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)

Phase 1

Telmisartan/S-Amlodipine